NCCM
NKTR icon

Nine Chapters Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Nine Chapters Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,200
Closed -$398K – 1086
2014
Q3 		$398K Buy
+2,200
New +$421K 0.04% 608

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Nine Chapters Capital Management's NKTR Position: Q4 2014 in Review

Nine Chapters Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2014, closing a stake of 2,200 shares — an estimated $398K sold.

Nine Chapters Capital Management first reported a position in NKTR in Q3 2014 and held it in 1 quarter. The position peaked at $398K in Q3 2014. 163 funds tracked by Wall St. Rank hold NKTR as of Q4 2014.

  • Nine Chapters Capital Management reported no remaining Nektar Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Nine Chapters Capital Management sold 2,200 Nektar Therapeutics shares in Q4 2014, an estimated $398K.
  • Nine Chapters Capital Management first reported a position in Nektar Therapeutics in Q3 2014 and held it in 1 quarter.
  • Nine Chapters Capital Management's Nektar Therapeutics position peaked at $398K in Q3 2014.
  • 163 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2014.

Based on Nine Chapters Capital Management's 13F filing for Q4 2014, filed 9 Feb 2015.